医疗创新ETF(516820)涨近1%，港股医药ETF(159718)交投活跃，机构：可以逢低布局医药板块

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing a strong upward trend, with significant increases in key stocks and ETFs, driven by favorable policies and innovations in the industry [1][2][4]. Group 1: Market Performance - As of April 30, 2025, the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Composite Index (930965) rose by 1.05%, with notable increases in stocks such as MicroPort Scientific Corporation-B (02252) up 11.12% and BeiGene (06160) up 5.97% [1]. - The Hong Kong Pharmaceutical ETF (159718) increased by 0.56%, with a recent price of 0.72 HKD, and has seen a 1.56% rise over the past week, ranking among the top in its category [1][2]. - The CSI Pharmaceutical and Medical Device Innovation Index (931484) rose by 0.81%, with stocks like Kelun Pharmaceutical (002422) up 5.83% and East China Pharmaceutical (000963) up 2.70% [4]. Group 2: Trading Activity - The Hong Kong Pharmaceutical ETF recorded a turnover rate of 28.85% during trading, with a total transaction volume of 74.15 million HKD, indicating active market participation [2]. - The ETF's average daily trading volume over the past week was 112 million HKD, and it has seen a significant growth in scale, increasing by 57.33 million HKD this month, leading its category [2]. Group 3: Regulatory and Policy Developments - The Hainan Provincial Government is promoting the rapid clinical use of innovative drugs and medical devices through policy guidance and inter-departmental collaboration, aiming for high-quality development in the biopharmaceutical industry [2]. - The National Medical Products Administration (NMPA) is conducting research to enhance regulatory efficiency and support innovation in drug development, emphasizing the need for comprehensive reforms in drug regulation [2]. Group 4: Investment Opportunities - The current market conditions, including the integration of "Artificial Intelligence +" in medical applications and the emergence of new healthcare business models, present potential investment opportunities in the pharmaceutical sector [2]. - The valuation of the Hong Kong Pharmaceutical ETF, with a price-to-earnings ratio (PE-TTM) of 23.91, is at a historical low, suggesting a favorable entry point for investors [4].